Odomzo (sonidegib) is a hedgehog pathway inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.
Sun Pharmaceutical Industries Europe B.V.
MEDICINE APPROVED BY
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Therapeutic Goods Administration (TGA)